SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.
Clinical trial NCT07614412 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07614412
- Sponsor
- Ministry of Health, Saudi Arabia
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2027-01-01
- Primary completion
- 2028-01-31
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.